Tail Vein Injection Techniques for Systemic Delivery of Nucleic Acids in Rats
Tail vein injection remains a foundational technique for achieving systemic delivery of nucleic acids in rat models, enabling widespread biodistribution of plasmid DNA, siRNA, shRNA, and mRNA for research in gene therapy, disease modeling, and pharmacogenomics. The success of tail vein injection depends heavily on technical execution, solution formulation, and volume-to-weight ratio, as well as the physical properties of the delivery vehicle. Because rats have relatively small, fragile tail veins with low tolerance for large-volume administration, careful preparation and handling are critical to ensure successful delivery without extravasation or local tissue damage.
The injection volume typically ranges from 5 to 10 mL/kg of body weight, with careful attention to the maximum tolerated volume, which varies by age and strain. For hydrodynamic injections—often used to enhance delivery to the liver—a bolus injection of a large volume (8–10% of body weight) is rapidly administered within 5–10 seconds, temporarily increasing venous pressure and creating transient fenestrations in vascular endothelium. This technique dramatically increases the uptake of naked plasmid DNA in hepatocytes but requires anesthesia and close monitoring due to the cardiovascular strain it imposes. For non-hydrodynamic delivery of formulated nucleic acids, smaller volumes of isotonic solutions are injected over a 30–60 second interval, using a 26–30 gauge needle and pre-warmed tail veins to improve venous access.
The formulation of nucleic acids with delivery agents—such as cationic lipids, polymeric nanoparticles, or lipid–polymer hybrids—improves cellular uptake and protects cargo from nuclease degradation in circulation. PEGylation of carriers enhances circulation time and reduces clearance by the reticuloendothelial system, improving the chances of reaching extrahepatic tissues. The biodistribution pattern following tail vein injection depends on particle size, surface charge, and ligand targeting. For example, nanoparticles under 100 nm with neutral or slightly negative charge tend to accumulate in the liver, spleen, and lungs, while smaller or actively targeted particles can reach tissues like the kidney, heart, or tumors.
Expression or silencing efficiency following tail vein injection is quantified by qPCR, Western blotting, and bioluminescence imaging, depending on the cargo. Inflammatory responses are evaluated by measuring serum cytokines such as IL-6 and TNF-α, and histological analysis of major organs is used to assess tissue integrity and immune infiltration. Repeated injections require particular caution, as the formation of neutralizing antibodies or cumulative toxicity may compromise effectiveness and safety. Anticoagulants like heparin are occasionally used to maintain vascular patency during serial administrations.
In sum, tail vein injection provides a reproducible and scalable route for systemic nucleic acid delivery in rats, particularly when combined with optimized nanoparticle systems and precise injection technique. This method supports a wide array of preclinical studies ranging from gene therapy evaluation to systemic RNAi validation and remains indispensable in the field of nonviral gene delivery.